Menu

Caffeine-Triggered Cells Help Control Blood Sugar in Diabetic Mice

Scientists engineered human cells to produce a molecule that stimulates insulin secretion in the presence of caffeine.

Jun 20, 2018
Diana Kwon

PIXABAY, ALEXAS_FOTOS

Scientists have engineered human cells that boost the production of insulin in response to caffeine. These modified cells could one day help treat patients with type 2 diabetes, researchers suggested in their report, published yesterday (June 19) in Nature Communications.

“You could completely integrate this into your lifestyle,” study coauthor Martin Fussenegger, a biotechnologist at the Swiss Federal Institute of Technology in Zurich, tells The Guardian. “You have a tea or coffee in the morning, another after lunch, and another at dinner, depending on how much drug you need to get your glucose back down.”

Fussenegger and his colleagues engineered human embryonic kidney cells that produce a synthetic version of human glucagon-like peptide 1 (GLP-1), a molecule that prompts the release of insulin, in the presence of caffeine.

Then, the team injected diabetic mice with an implant containing hundreds of the engineered cells. This revealed that the animals’ blood-sugar levels could be controlled by simply adding a caffeinated beverage, such as coffee, cola, or Red Bull, to their meals. Noncaffeinated beverages, such as herbal tea and chocolate milkshakes, had no effect.

Such implants are unlikely to be accidently triggered by other foods or beverages, Fussenegger tells New Scientist. “[V]ery small trace amounts of caffeine will not trigger the system,” he says.

Although the technique is still in the early stages of development, if it proves to be safe and effective in humans, it could one day replace insulin injections, Fussenegger tells The Guardian. “You could have your normal life back,” he says. “The implant could last for six months to a year before it would need to be replaced.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.